MIND Diet and Cognitive Decline; Gene Therapy for Parkinson’s; Curbing MS Fatigue

The MIND diet was associated with slower cognitive decline in both Black and white older adults, but relationships appeared to vary with other lifestyle and vascular factors. (Alzheimer’s and Dementia)

A meta-analysis identified causal genetic effects of brain volumes in attention deficit-hyperactivity disorder and Parkinson’s disease. (Nature Genetics)

A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase (GAD) gene to the subthalamic nucleus to boost levels of GABA, was safe, well tolerated, and showed improvement in motor scores in a small Parkinson’s trial, MeiraGTx said.

CVN424, a GPR6 inverse agonist, also was safe, well tolerated, and showed a clinically meaningful reduction in daily “off” time at 150 mg/day in Parkinson’s disease, a phase II study showed. (eClinicalMedicine)

A tool to predict which patients are at risk of epilepsy after a cerebral venous sinus thrombosis was published in JAMA Neurology.

A group of experts led by the American Headache Society, together with the National Institute of Neurological Disorders and Stroke and the International Headache Society, identified eight research priorities for the headache field.

Modafinil (Provigil), cognitive behavioral therapy, and a combination of the two were associated with similar reductions in the effects of multiple sclerosis (MS) fatigue at 12 weeks, the COMBO-MS trial showed. (Lancet Neurology)

Compared with conventional therapies, the risk of inflammatory central nervous system diseases rose after anti-tumor necrosis factor therapy across all indications, a meta-analysis found. (JAMA Neurology)

Mailed educational interventions directed at patients, caregivers, and clinicians didn’t reduce inappropriate prescribing of certain high-risk medications for people with Alzheimer’s and dementia. (JAMA Internal Medicine)